Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
DOYLESTOWN, Pa., June 25, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses.
ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation.
"Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies," said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. "We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025."
The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on clinicaltrials.gov.
ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity.
About Metabolics PharmaMetabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit www.metabolicspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625436712/en/
Contacts
Company contact: Richard Larson, M.D., Ph.D.Chief Executive Officer, Chief Medical Officer, and Chairman of the BoardJohn DessoukiChief Financial Officerj.dessouki@metabolicspharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection
Dr. Lal PathLabs has taken a groundbreaking step in advancing cancer diagnostics in India by becoming the first laboratory in the country to introduce a deep learning-based AI module for the detection of lymph node metastasis, including micrometastasis. This innovation, developed in collaboration with Singapore-based healthtech company Qritive, was recently showcased at USCAP 2025, one of the most prestigious pathology conferences in the world. The accurate detection of cancer spread to lymph nodes is a critical factor in determining the stage and treatment strategy for patients. Missing these signs of cancer progression can allow the disease to advance, increasing the chances of it spreading to distant organs and reducing survival rates. The ability to identify even occult metastases in patients with early-stage cancer has the potential to significantly influence treatment plans and improve outcomes. Traditionally, detecting micrometastases—small clusters of cancer cells hidden in lymph nodes—has been a time-consuming and complex process, often requiring advanced testing. The new AI system, called QiAI Lymph Node Dx, addresses this challenge by using deep learning to analyze digital slides and identify cancer cells with exceptional precision. This integration of AI into diagnostic practice ensures that cancer detection becomes faster, more reliable, and highly accurate. What makes this development especially impactful is its ability to pick up even single cancer cells, which were later validated through immunohistochemistry testing. The AI model has been tested across various cancer types, including breast, colon, stomach, and esophageal cancers, consistently delivering highly accurate results. Breast cancer, which accounts for nearly 28% of cancer cases among women in India, particularly stands to benefit from this breakthrough, highlighting the clinical relevance of the technology. By achieving complete sensitivity and negative predictive value—meaning no metastatic cases went undetected—the AI system has proven to be a robust screening tool. Its tumor-agnostic design allows it to function effectively across different cancer types, making it a versatile solution for oncologists and pathologists alike. As cancer incidence continues to rise in India, the integration of advanced AI-powered diagnostic tools such as QiAI Lymph Node Dx is set to transform the landscape of cancer care. By enabling earlier and more accurate diagnoses, this technology not only improves the efficiency of medical practice but also ensures better treatment decisions, offering renewed hope to patients battling cancer. Ahmedabad Plane Crash
2 hours ago
New malaria drug for babies offers hope to health workers in Uganda
KAMPALA, Uganda -- Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early.' Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (nearly 4½ to 11 pounds). Swissmedic said the treatment, a sweet-tasting tablet that disperses into a syrup when dropped into water, was approved in coordination with the World Health Organization under a fast-track authorization process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than 5 and pregnant women, according to WHO. Nigeria, Congo and Uganda — in that order — are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitizing the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centers across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria.' In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control program, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the U.S. shrank its foreign aid program earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programs such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under 5 years,' she said. ___
Business Journals
3 hours ago
- Business Journals
Atlas Men's Health to open first Manhattan clinic
Atlas Men's Health will open its first Manhattan location this fall. The Long Island-based men's health clinic will occupy a 3,800-square-foot space on the sixth floor of 505 Eighth Ave. in Midtown. The location will serve as the clinic's general and executives offices as well as a site for patient consultations and services. The lease is for five years. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events GFP Real Estate, the landlord, was represented in-house by Allen Gurevich while Atlas Men's Health was represented by Inc.'s Uriel Gandelman on the deal. 'Atlas is opening a location in Midtown Manhattan to make care more accessible for patients who live or work in the city,' Jenny Kaur, regional director at Atlas Men's Health, said in an email statement. 'By expanding into Midtown, Atlas is meeting the growing demand for men's health services while providing greater convenience and visibility in a central location.' Atlas Men's Health currently has one location in Long Island's East Meadow hamlet. The new tenant will join a roster at 505 Eighth Ave. that includes advertising company Mesmerize Media, nonprofit Cicatelli Associates Inc. and law firm Shankar Ninan & Co. LLP. The 25-story, 275,000-square-foot office building, which was originally known as the Hoover Building, features a modernized, 24/7 attended lobby. Sign up for the Business Journal's free daily newsletter to receive the latest business news impacting New York.
